Randomized phase II trials: a long-term investment with promising returns
about
Future prospects of therapeutic clinical trials in acute myeloid leukemia.A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.Resampling phase III data to assess phase II trial designs and endpoints.Accelerated approval and breakthrough therapy designation: oncology drug development on speed?Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trialsNCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug AdministrationDo single-arm trials have a role in drug development plans incorporating randomised trials?Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learnedPancreatic cancer: why is it so hard to treat?Targeting developmental pathways in children with cancer: what price success?Estimation of renal cell carcinoma treatment effects from disease progression modelingRole of randomized phase III trials in an era of effective targeted therapies.Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.Recent progress in canine tumor vaccination: potential applications for human tumor vaccines.Accounting for uncertainty in the historical response rate of the standard treatment in single-arm two-stage designs based on Bayesian power functions.A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.More randomization in phase II trials: necessary but not sufficient.Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.Exploratory trials in mental health: anything to learn from other disciplines?Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.Minimally invasive in tumor multidrug comparative analysis with contrast-enhanced MRI in mice.
P2860
Q30244168-3B8FF693-9A83-43E2-85B0-7D1EC18C645AQ33401816-E85DC5CF-6858-4EAF-A700-2855A1B3F967Q34144413-14642592-107C-4E21-89BD-B1FED9EBE4DCQ34204153-85E25186-79CC-4B7F-9E5B-55C2C1054BC9Q34716556-B3EA6212-464A-4BA1-AFBD-91665C882A0AQ36507559-4FE61C54-53C8-48BC-BF0F-B44ACDE66536Q36565598-B77E7C69-3E4E-4DE6-A730-8FE831EDA0E7Q36866317-C2E4F749-F145-465E-AA8E-AD7A2121F2D9Q36871673-9D3C2371-AF65-416B-B7B8-E275EDFD9BB5Q36886497-3EA0756E-45EA-4EF4-AC49-B70392A2505EQ36905620-6247DEE2-C1BF-4E6C-AFFB-FA8B4F81D717Q37217573-A5F8B24F-F700-4577-AD25-B18E32C4E81CQ37964935-6522977B-7104-4456-92B3-D7D37583E91AQ38025261-00DABBE8-4DAB-4AFA-AD19-874864C2ACC5Q38068234-5F7D67F6-AE80-465F-8AC2-4E990DFF6F9EQ39263674-315D6DA0-564F-45A1-9CF6-4DCEFB09CFF7Q41643154-A595CC37-41B9-45C3-B581-3C5FC8A33F66Q42828526-0BD30111-43DB-4BF4-AD5C-8A69933445BFQ45718951-2A218D59-46E1-490C-BBC2-FD1E6A86ABBAQ47832169-A47330AA-4D37-4C95-98EE-3AC742812A46Q51081422-E3680713-C61C-49C3-965F-D4E17A65C72CQ51722815-3E726044-DDAF-4463-8678-8179FE8235C3
P2860
Randomized phase II trials: a long-term investment with promising returns
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Randomized phase II trials: a long-term investment with promising returns
@ast
Randomized phase II trials: a long-term investment with promising returns
@en
type
label
Randomized phase II trials: a long-term investment with promising returns
@ast
Randomized phase II trials: a long-term investment with promising returns
@en
prefLabel
Randomized phase II trials: a long-term investment with promising returns
@ast
Randomized phase II trials: a long-term investment with promising returns
@en
P2860
P356
P1476
Randomized phase II trials: a long-term investment with promising returns
@en
P2093
Manish R Sharma
Walter M Stadler
P2860
P304
P356
10.1093/JNCI/DJR218
P407
P577
2011-06-27T00:00:00Z